ArticleFrontiers in immunology2025
Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Castration-resistant prostate cancer (CRPC) has a poor prognosis and requires novel therapeutic approaches. Previously, we discovered that a high dose of human peripheral blood-derived natural killer (PB-NK) cells can have antitumor effects against CRPC. However, whether antibodies against prostate-specific membrane antigen (PSMA) can direct adoptive NK cells to the tumor site and therefore decrease NK cell dosage through antibody-dependent cellular cytotoxicity remains unknown. Methods: NK cells were obtained from the blood samples of healthy donors. To engineer an anti-PSMA antibody (Ab), a llama was immunized with human PSMA protein, and the anti-PSMA variable domains of camelid heavy-chain antibody (VHH) clones were isolated using phage display. The VHH was recombinantly fused with the human Fc region to produce an anti-PSMA Ab. Results: We constructed an anti-PSMA Ab and validated its high affinity toward the PSMA antigen. CD16 is abundantly expressed in PB-NK cells. The anti-PSMA Ab significantly enhanced the cytotoxicity of NK cells against CRPC cells Conclusion: Combined treatment with anti-PSMA Ab and human PB-NK cells improves antitumor efficacy against CRPC and is a promising approach to treating CRPC in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.